Authors: Wagenaar, HC Pecorelli, S Mangioni, C van der Burg, MEL Rotmensz, N Anastasopoulou, A Zola, P Veenhof, CHN Lacave, AJ Neijt, JP van Oosterom, AT Einhorn, N Vermorken, JB

Citation: Hc. Wagenaar et al., Phase II study of mitomycin-C and cisplatin in disseminated, squamous cellcarcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study, EUR J CANC, 37(13), 2001, pp. 1624-1628

Authors: Duffaud, F van der Burg, MEL Namer, M Vergote, I Willemse, PHB Huinink, WT Guastalla, JP Nooij, MA Kerbrat, P Piccart, M Tumolo, S Favalli, G van der Vange, N Lacave, AJ Wils, J Splinter, TAW Einhorn, N Roozendaal, KJ Rosso, R Vermorken, JB

Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162

Authors: Vergote, I De Brabanter, J Fyles, A Bertelsen, K Einhorn, N Sevelda, P Gore, ME Kaern, J Verrelst, H Sjovall, K Timmerman, D Vandewalle, J Van Gramberen, M Trope, CG

Citation: I. Vergote et al., Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, LANCET, 357(9251), 2001, pp. 176-182

Authors: Blegen, H Einhorn, N Sjovall, K Roschke, A Ghadimi, BM McShane, LM Nilsson, B Shah, K Ried, T Auer, G

Citation: H. Blegen et al., Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas, INT J GYN C, 10(6), 2000, pp. 477-487

Authors: Einhorn, N Bast, R Knapp, R Nilsson, B Zurawski, V Sjovall, K

Citation: N. Einhorn et al., Long-term follow-up of the Stockholm screening study on ovarian cancer, GYNECOL ONC, 79(3), 2000, pp. 466-470

Authors: Einhorn, N Lundell, M Nilsson, B Ragnarsson-Olding, B Sjovall, K

Citation: N. Einhorn et al., Is there place for radiotherapy in the treatment of advanced ovarian cancer?, RADIOTH ONC, 53(3), 1999, pp. 213-218